Introduction {#Sec1}
============

Central venous oxygen saturation (S~cv~O~2~) has long been studied as a prognostic marker and resuscitation end-point in patients with shock \[[@CR1]\]. It is an imperfect surrogate of mixed venous oxygen saturation (S~v~O~2~) because it reflects the oxygen supply-to-consumption ratio of the upper part of the body only. However, S~cv~O~2~ is simple to measure either continuously or intermittently, and spontaneous or therapy-induced changes in S~cv~O~2~ and S~v~O~2~ are closely correlated \[[@CR2]\].

Based on these principles, Rivers *et al*. \[[@CR3]\] showed that an early therapeutic strategy that includes aiming for the rapid normalization of S~cv~O~2~ (≥70%) in patients suffering from severe sepsis or septic shock at presentation to the emergency department could improve survival. Since then, international guidelines have recommended targeting S~cv~O~2~ at ≥70% during the first 6 hours of care in patients presenting with severe sepsis or septic shock \[[@CR4]\]. However, this recommendation remains controversial. Indeed, resuscitation protocols including an S~cv~O~2~ target have been mostly tested in the emergency department \[[@CR5]-[@CR7]\], not after ICU admission. Importantly, after ICU admission, targeting normal S~cv~O~2~ is deemed to have little place, as S~cv~O~2~ is frequently considered to be already normalized on ICU admission \[[@CR8]\]. However, the prevalence of low S~cv~O~2~ (\<70%) in ICU septic patients is poorly known. It has been assessed only in two prospective studies of limited size \[[@CR9],[@CR10]\], while other studies have only reported the mean initial value of S~cv~O~2~ \[[@CR8],[@CR11]\]. In addition, the relationship between low S~cv~O~2~ and outcome is still unknown.

Since the Rivers study \[[@CR3]\], the idea that the relationship between low S~cv~O~2~ and fatal outcome in septic patients has been widely demonstrated has remained. Up to now, however, such a relationship has not been demonstrated in multicentre prospective studies performed either in the emergency department \[[@CR12]\] or in the ICU \[[@CR10]\]. Accordingly, the aim of the present multicentre observational prospective study was to estimate the prevalence of low S~cv~O~2~ in patients presenting with severe sepsis or septic shock after ICU admission, and to assess its potential association with outcome.

Materials and methods {#Sec2}
=====================

The study took place in 10 French medical-surgical adult ICUs (4 university hospitals, 1 regional and teaching hospital, and 5 general hospitals) with a combined total of 154 ICU beds. Participating ICUs were asked to screen consecutive patients presenting with sepsis and circulatory failure for potential inclusion in the study, over a period left at their discretion, from July 2011 to June 2012.

Clinicians were asked to include patients with severe sepsis or septic shock, preferably within 6 hours of ICU admission, and as soon as possible without changing routine practice. Patients were included if they had circulatory failure of septic origin (that is, severe sepsis or septic shock \[[@CR13]\]) within 12 hours after ICU admission, and had an intra-arterial and superior vena cava (internal jugular or subclavian) catheter in situ. Circulatory failure was defined by either the use of vasopressor (septic shock) or, in case of severe sepsis, by a mean arterial pressure \<65 mmHg or a systolic arterial pressure \<90 mmHg at least twice over a 15-minute period, associated with at least one condition reflecting tissue hypoperfusion or low flow state (see Table [1](#Tab1){ref-type="table"}, Criteria for circulatory failure at inclusion). Patients were not included in the case of brain death, admission following cardiac arrest, or if imminent death was expected.Table 1**Demographics, clinical characteristics, treatment and outcome in 363 patientsVariableValueMale sex**231 (63.6)**Age, years**65.8 ± 14.1**Severe sepsis at inclusion**25 (6.9)**Septic shock at inclusion**338 (93.1)**Nosocomial infection**98 (27.0)**Source of infection**Lung-pleura165 (45.7)Abdomen83 (23.0)Urine45 (12.5)Skin, bones, joints30 (8.3)Catheter7 (1.9)Central nervous system6 (1.7)Endocarditis6 (1.7)Other8 (2.2)Source not identified11 (3.0)**Underlying disease**Chronic obstructive pulmonary disease63 (17.4)Arterial hypertension198 (54.5)Chronic heart failure36 (9.9)Liver cirrhosis27 (7.4)Chronic haemodialysis8 (2.2)Type 1 diabetes15 (4.1)Type 2 diabetes85 (23.4)Immunocompromized state110 (30.3)Active solid cancer45 (12.4)Active lymphoma or leukaemia22 (6.1)Myeloproliferative syndrome12 (3.3)Recent (\<6 months) chemotherapy or radiotherapy42 (11.6)Neutropenia (absolute neutrophil count \<1,000/mm^3^)27 (7.4)HIV seropositivity4 (1.1)Solid organ or bone marrow transplantation6 (1.7)Steroids therapy41 (11.3)Other immunosuppressive therapy14 (3.9)**Criteria for circulatory failure at inclusion (in addition to recent or ongoing hypotension)**Tachycardia (heart rate \>110 beats/minute)195 (53.7)Urine output \<0.5 mL/hour per Kg of body weight147 (40.5)Capillary refill time \>2 seconds48 (13.2)Cyanosis in the absence of severe hypoxemia56 (15.4)Skin mottling167 (46.0)Altered consciousness77 (21.2)Arterial lactate \>2 mmol/L on admission190 (52.3)Epinephrine or norepinephrine administration338 (93.1)**Therapy**Invasive mechanical ventilation on admission128 (35.2)Invasive mechanical ventilation during ICU stay305 (84.0)Norepinephrine on admission136 (37.5)Epinephrine on admission10 (2.8)Norepinephrine or epinephrine during ICU stay356 (98.1)Dobutamine on admission12 (3.3)Transfusion of blood products between zero hours and 24 hours58 (16.6)Renal replacement therapy during ICU stay84 (23.1)**Initial arterial blood lactate concentration, mmol/L** ^**a**^3.2 ± 3.0median 2.2 (IQR 0.95 to 4.45)**McCabe classification** \[[@CR14]\]  0223 (61.4)  196 (26.4)  244 (12.1)**Simplified acute physiology score II** \[[@CR15]\]56.8 ± 20.0**SOFA score** \[[@CR16]\] **(highest value from H0 to H24)**10.3 ± 3.4**ICU death**102 (28.1)**Day-28 death**111 (30.6)Categorical variables are expressed as absolute counts (%) and continuous variables as mean ± SD unless otherwise specified. ^a^Initial arterial blood lactate concentration was available in 358/363 patients (not measured in 5 patients because of technical problem). SOFA, Sequential organ failure assessment.

Measurements and data collection {#Sec3}
--------------------------------

The measurement of S~cv~O~2~ was performed as soon as possible (at the time defined as zero hours (H0)) by sampling blood from the superior vena cava through the central venous catheter, and at 6 hours after inclusion (H6). S~cv~O~2~ was either calculated from blood gas analysis by a standard blood gas analyser in four centres, or measured by a co-oximeter in six centres. Concomitantly, arterial blood was drawn at each time point for blood gas analysis and lactate measurement. Other demographic, clinical and laboratory data prospectively recorded are provided in Additional file [1](#MOESM1){ref-type="media"}. Independent data monitoring was conducted in each site to ascertain the accuracy of recorded information.

The Ethics Committee of the teaching hospital of Limoges, France, approved the protocol for all hospitals involved (agreement number 65-2011-11) and waived the need for prior informed consent because the study procedures fulfilled the criteria of a non-interventional study as defined by the French Law \[[@CR17]\]. Patients' next-of-kin and then patients themselves if they regained capacity were informed of their participation and their right to refuse the use of the obtained data was clearly established.

Haemodynamic monitoring and treatment of shock followed international \[[@CR18]\] and national guidelines \[[@CR19]\] that corresponded to standard of care of the participating centres. However, none of the participating ICUs had implemented systematic treatment algorithms based on S~cv~O~2~ monitoring.

Study objective {#Sec4}
---------------

The study primary objective was to estimate the prevalence of low S~cv~O~2~ (\<70%, but other thresholds were also tested) and to assess the possible association between low S~cv~O~2~ and day-28 mortality.

Data reporting and statistical analysis {#Sec5}
---------------------------------------

Categorical data are expressed as percentages, and continuous variables are expressed as means ± SD or medians and IQR, as appropriate. The prevalence and 95% CI of S~cv~O~2~ \< 70% was estimated taking into account participating centres as a random effect \[[@CR20]\]. The S~cv~O~2~ \< 70% and other thresholds of initial S~cv~O~2~ values determined by locally weighted scatterplot smoothing (LOWESS) \[[@CR21]\] were examined for their potential association with day-28 mortality.

Each given threshold of the initial S~cv~O~2~ value was entered in a mixed-effect logistic regression model, with participating centres entered as a random effect, and adjusted for all covariables available at H0 and linked to day-28 mortality with a *P*-value \<0.15, by univariate analysis. The covariables were eliminated using the backward method until the final logistic model with the best fit (as assessed by the Akaike information criterion \[[@CR15]\]) was reached. Based on the results of a retrospective study performed in one participating ICU \[[@CR22]\], we calculated that 1-year study duration would allow the inclusion of at least 350 patients with 100 fatalities, which would allow multivariate evaluation of ten covariables, including S~cv~O~2~.

We re-ran the logistic analyses in predefined subgroups of patients (for example, mechanical ventilation or not at H0, patients below or above median values of continuous variables such as initial lactate level or amount of volume expansion before inclusion, et cetera).

Percentages were compared using the Fisher exact test, chi-square test, or chi-square test for trend (Cochran-Armitage test), and continuous variables were compared using the unpaired Student *t*-test or by analysis of variance when appropriate. Unadjusted comparisons of survival curves were performed using the log-rank test. Adjusted odds ratios (OR) are given with the 95% CI. A two-tailed *P*-value \<0.05 was considered statistically significant. Mixed-effect logistic regression was performed using the lme4 package of R 2.15.2 \[[@CR23]\].

Results {#Sec6}
=======

We screened 670 patients with severe sepsis or septic shock. Among them, 363 patients were enrolled (Figure [1](#Fig1){ref-type="fig"}). The Simplified acute physiology score (SAPSII) \[[@CR24]\] and ICU death rates were similar in enrolled and non enrolled patients (see Additional file [2](#MOESM2){ref-type="media"}).Figure 1**Flow diagram.**

Demographic and clinical characteristics are shown in Table [1](#Tab1){ref-type="table"}. The median time between ICU admission and inclusion (H0), and between the time at which criteria for inclusion were satisfied and inclusion, was 211 minutes (IQR 83 to 339) and 189 minutes (IQR 84 to 292), respectively. The median time between severe sepsis identification and inclusion (H0) was 7.6 hours (IQR 2 to 13.2). Details of resuscitation administered before inclusion and time of inclusion in patients classified according to their origin (transferred from another hospital, from the ward, or from the emergency department) are shown in Table [2](#Tab2){ref-type="table"}.Table 2**Time of inclusion and resuscitation administered before inclusionPatients transferred from another hospitalPatients transferred from the wardPatients transferred from the emergency department(n = 93)(n = 95)(n = 175)**Patients intubated before inclusion73 (78%)72 (77%)118 (67%)Amount of fluid administered before inclusion, mL/Kg of body weight313536(12 to 50)(19 to 51)(20 to 52)Patients treated with vasopressors before inclusion (epinephrine or norepinephrine)84 (88%)82 (90%)155 (89%)Dosage of vasopressors (epinephrine + norepinephrine), μg/Kg/min0.30.260.40(0.09 to 0.51)(0.12 to 0.38)(0.13 to 0.66)Patients treated with dobutamine before inclusion3 (3%)3 (3%)10 (6%)Time between severe sepsis identification and inclusion, minutes482396468(220 to 510)(40 to 847)(188 to 696)Time between ICU admission and inclusion, minutes185246206(53 to 317)(92 to 400)(97 to 315)Time between satisfaction of inclusion criteria and inclusion, minutes231161185(110 to 352)(60 to 262)(93 to 277)Continuous variables are expressed as median and IQR, and categorical variables as number (%).

The mean initial S~cv~O~2~ value was 74.1 ± 11.0% and was not different between survivors and non survivors at day 28 (74.6 ± 10.0% versus 73.0 ± 12.9%, respectively; *P* = 0.21).

Prevalence of low initial S~cv~O~2~ {#Sec7}
-----------------------------------

Initial S~cv~O~2~ \< 70% was present in 111 patients and the pooled estimate for its prevalence, taking into account participating centres as a random effect, was 27% (95% CI 18%, 37%). At H0, 136 patients (37%) had reached the classic clinical endpoints for mean arterial pressure (≥65 mmHg), central venous pressure (≥8 mmHg), and urine output (≥0.5 mL/Kg of body weight). Among them, 32% (43/136) had an initial S~cv~O~2~ \< 70%, with normal lactate concentration (≤2 mmol/L) in 21 (49%) patients. At H0, 166 patients (46%) had normal lactate concentration (≤2 mmol/L). Among them, 55 (33%) had an initial S~cv~O~2~ \< 70%. The delay between severe sepsis identification and inclusion and the amount of fluids administered for resuscitation before inclusion had no influence on the mean initial S~cv~O~2~ values or on the proportions of patients with initial S~cv~O~2~ \< 70% (see Additional file [3](#MOESM3){ref-type="media"}).

Crude day-28 death rate and initial S~cv~O~2~ level {#Sec8}
---------------------------------------------------

As determined by visual inspection of the LOWESS plot (see Additional file [4](#MOESM4){ref-type="media"}), we assessed the association between day-28 mortality and initial S~cv~O~2~ \< 70%, \<75%, and \>85%. The day-28 death rate was significantly higher in patients with initial S~cv~O~2~ \< 70% than in patients with initial S~cv~O~2~ ≥ 70% (42/111 (37.8%) versus 69/252 (27.4%), respectively; *P* = 0.049), whereas it was similar in patients with initial S~cv~O~2~ below or above the other thresholds examined (all *P*-values \>0.35) (see Additional file [5](#MOESM5){ref-type="media"}: Table E8).

Association between S~cv~O~2~ and mortality when adjusted for potential confounders {#Sec9}
-----------------------------------------------------------------------------------

The initial S~cv~O~2~ entered in the logistic model as a continuous variable was negatively linked to day-28 mortality: OR = 0.96 (95% CI 0.93, 0.99) for each 1% increase in initial S~cv~O~2~; *P* = 0.004 (see Additional file [5](#MOESM5){ref-type="media"}: Table E9). An initial S~cv~O~2~ \< 70% was significantly and independently associated with day-28 mortality (OR = 3.60, 95%CI 1.76, 7.36; *P* = 0.0004) (Table [3](#Tab3){ref-type="table"}), a trend consistently observed across the different subgroups examined (Figure [2](#Fig2){ref-type="fig"}).Table 3**Logistic regression analysis of 28-day mortality in 363 septic patients, with initial S** ~**cv**~ **O** ~**2**~ **value below 70** ***%*** **adjusted for the other confoundersCovariables** ^**a**^**Adjusted odds ratio** ^**b**^**95% CI*P*** **-value**SAPSII (for each 1 point increase)1.051.03, 1.07\<0.00001Initial S~cv~O~2~ \< 70%3. 601.76, 7.360.0004Arterial lactate (for each 1 mmol/L increase)1.181.06, 1.320.002Initial arterial partial pressure in CO2 (for each 1 mmHg increase)1.041.01, 1.060.003McCabe class 1 (versus class 0)2.581.31, 5.100.006Abdominal sepsis2.561.25, 5.230.010McCabe class 2 (versus class 0)3.091.24, 7.720.016Male gender2.141.11, 4.130.022Initial body temperature (for each 1C° increase)0.780.62, 0.980.031Exposure to ACE inhibitors or ARB in the past 48 hours0.500.26, 0.980.044^a^All covariables entered in the model were variables linked to day-28 mortality with *P* \<0.05 on univariate analysis, and selected using the backward method. ^b^For each continuous covariable odds ratios are given per each unit of the given covariable. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; SAPSII, Simplified acute physiology score; S~cv~O~2~, central venous oxygen saturation.Figure 2**Forest plot for subgroup analysis.** ^a^All cutoff values provided in the figure for demographic, clinical or laboratory variables are median values calculated on the whole study population. ^b^Sequential organ failure assessment (SOFA) score is the highest value during the first 24 hours after enrollment. ^c^With the use of a cutoff of 2 mmol/L for lactate, the odds ratio for day-28 death (OR) was 1.29 (0.54, 3.05) in the case of lactate \>2 mmol/L, and 4.59 (1.79, 11.84) in the case of lactate ≤2 mmol/L. ^d^Vasopressor dose = continuous intravenous (iv) norepinephrine dose plus continuous iv epinephrine dose. ^e^Left ventricular ejection fraction assessed by transthoracic echocardiography before 24 hours after enrollment. ^f^Haemoglobin concentration was taken into account only if measured between 6 hours before and 6 hours after enrollment. SAPSII, Simplified acute physiology score; ScvO2, central venous oxygen saturation.

An initial S~cv~O~2~ \< 75% was also significantly associated with day-28 mortality (OR = 2.15, 95% CI 1.16 to 3.98; *P* = 0.015) (see Additional file [5](#MOESM5){ref-type="media"}: Table E10).

Evolution of S~cv~O~2~ and relationship to lactate concentration {#Sec10}
----------------------------------------------------------------

The evolution of S~cv~O~2~ between H0 and H6 was similar between survivors and non survivors on day 28 (see Additional file [6](#MOESM6){ref-type="media"}: Figure E3). However, by logistic regression analysis, a S~cv~O~2~ \< 70% at H6 still appeared as a risk factor for day-28 death (OR = 2.18, 95% CI 1.12, 4.26; *P* = 0.022) (see Additional file [5](#MOESM5){ref-type="media"}: Table E11).

The proportion of patients with initial S~cv~O~2~ \< 70% was similar in the case of lactate above or below the median initial lactate value of 2.2 mmol/L (29% versus 33%; *P* = 0.3). Figure [3](#Fig3){ref-type="fig"} shows the survival curves and the crude death rates at day 28 in four patients' subgroups according to their lactate concentration and S~cv~O~2~ at H0 (for subgroups according to lactate and S~cv~O~2~ at H6 see Additional file [6](#MOESM6){ref-type="media"}: Figure E4). In subgroup analysis, the logistic regression showed that S~cv~O~2~ \< 70% was independently associated with day-28 death in patients with initial lactate level \<2.2 mmol/L (OR = 3.31) (Figure [2](#Fig2){ref-type="fig"}).Figure 3**Survival curve and death rate (%) at day 28 according to initial lactate level and central venous oxygen saturation (S** ~**cv**~ **O** ~**2**~ **).** The left part of the figure shows survival curves in four patients' subgroups according to their initial zero hours (H0) lactate concentration and S~cv~O~2~. The right part of the figure shows the day-28 death rate in each subgroup. Numbers inside the bars are number of non survivors/total number of patients in each subgroup. ^a^Unadjusted pair comparison of survival curves between the different subgroups were not statistically significant on log-rank test. ^b^There was no significant difference in crude death rate at day-28 among the four groups (chi-squared test). However, there was a significant global trend towards higher death rate from the condition with normal lactate and S~cv~O~2~ to the condition with high lactate and low S~cv~O~2~ (*P* \<0.001, Cochran-Armitage test).

Among the 335 patients with lactate and S~cv~O~2~ measured at H0 and H6, 148 (44%) had a satisfactory lactate clearance (defined as at least a 10% decrease between H0 and H6 \[[@CR25]\]) and 187 (56%) had not. The proportion of patients with S~cv~O~2~ \< 70% at H6 was similar in the case of satisfactory or not satisfactory lactate clearance (22% versus 23%, respectively). Additional file [6](#MOESM6){ref-type="media"}: Figure E5 shows the survival curves and the crude death rates at day-28 in four patients' subgroups according to their lactate clearance and S~cv~O~2~ at H0 and H6. On logistic regression, S~cv~O~2~ \< 70% at H6 was independently associated with day-28 mortality in the subgroup of patients with non satisfactory lactate clearance (OR = 2.32 (1.03, 5.23)) but not in patients with satisfactory lactate clearance (OR = 0.98 (0.21, 4.54)). Additional results for the roles played by initial respiratory conditions, haemoglobin concentration and body temperature in the prevalence of low S~cv~O~2~ and mortality are given in Additional file [7](#MOESM7){ref-type="media"}.

Discussion {#Sec11}
==========

The main finding of our study is that more than one quarter of septic patients had ScvO2 \< 70% in the first hours after ICU admission. Furthermore, low ScvO2 in the first hours of ICU admission (and/or 6 hours later) was independently associated with 28-day mortality. These data suggest that one quarter of septic patients admitted to the ICU could be candidates for ICU protocol-based therapy targeting ScvO2.

Prevalence of low ScvO2 {#Sec12}
-----------------------

In the present multicentre study, using ScvO2 measurements planned as early as possible in routine care, we report a 27% prevalence of low ScvO2 (\<70%). This value is below the 40% to 50% prevalence reported in the few, small sized, available prospective studies performed to date in the ICU \[[@CR9],[@CR10]\]. These studies analysed selected patients: one study analysed only half of the patients with lactate above 3 mmol/L enrolled in a comparative therapeutic trial \[[@CR9]\], and the other study excluded patients with malignancy \[[@CR10]\]. However, the 27% prevalence of low ScvO2 we observed in our study with few exclusion criteria represents a non negligible proportion of septic patients and does not support the view that low ScvO2 is uncommon after admission to the ICU \[[@CR5]-[@CR8]\].

Importantly, even when classic clinical endpoints of initial resuscitation were achieved (mean blood pressure (BP) \>65 mmHg, central venous pressure (CVP) \> 8 mmHg and urine output \>0.5/ml/Kg) low ScvO2 could not be ruled out as it was observed in one third of our apparently resuscitated patients. Furthermore, arterial lactate also misclassified patients in their low/high contemporaneous ScvO2: the prevalence of ScvO2 \< 70% was similar in the case of lactate above or below the median value of 2.2 mmol/L (29% versus 33%; *P* = 0.3). This underlines that ScvO2 measurement is not interchangeable with these routine clinical and biological data.

Association between low ScvO2 and outcome {#Sec13}
-----------------------------------------

As expected, the SAPSII score and the arterial lactate consistently appeared as powerful predictors of day-28 death. Independently of these two well-known predictors \[[@CR24],[@CR26]\], low initial ScvO2 was also consistently linked to day-28 mortality. To the best of our knowledge, this has never been previously shown in either emergency department or ICU studies. Of note, our study was not designed to assess whether the link between low ScvO2 and mortality is a causal relationship.

Clinical perspectives {#Sec14}
---------------------

One quarter of our septic patients had low ScvO2 in the first hours of ICU admission and this was associated with poor outcome. This was also the case for persisting low ScvO2 (at 6 hours after the first measurement). These patients could be candidates for ICU protocol-based therapy targeting the ScvO2 in addition to routine initial care. The choice between lactate-guided, ScvO2-guided therapy, or between both, is still under debate \[[@CR27]\]. In emergency department septic patients, there is no significant difference in patients' outcomes when managed either with lactate-guided or ScvO2-guided therapy \[[@CR28]\]. Interestingly, our results suggest that, rather than choosing one of these measurements, ScvO2 should be tested in combination with lactate monitoring because low ScvO2 may be present or persist even in the case of low lactate, or in the case of satisfactory lactate clearance (see Figure [3](#Fig3){ref-type="fig"} and Additional file [6](#MOESM6){ref-type="media"}). This later finding was also observed in studies performed in emergency department patients in the very early phase of resuscitation: Arnold *et al*. \[[@CR29]\] have shown that 15% of patients with good lactate clearance and 21% of patients with poor lactate clearance had S~cv~O~2~ \< 70%; in the study by Jones *et al*. \[[@CR28]\], an interventional, randomized trial comparing lactate clearance or S~cv~O~2~ \> 70% as therapeutic targets, the proportion of patients who did not have normalized ScvO2 was 19% in both groups. This proportion is lower than the one we observed but may not reflect what happens in real conditions, as resuscitation was performed per protocol for the purpose of the randomized trial. For their part, Jansen *et al*. \[[@CR9]\] compared usual care and protocol-based therapy with lactate clearance as a target in an ICU population of septic patients, and showed that at 6 hours, 33% of patients in the intervention group still had S~cv~O~2~ \< 70% while more than 40% had lactate clearance \>20%. Although these findings are consistent with ours, once again they may not reflect the real-life conditions as the patients were treated according to a rigorous and complex protocol. Therefore, to our knowledge, our study is the first to show that S~cv~O~2~ and lactate may show non parallel evolutions in septic patients cared for in the ICU in real-life conditions.

The usefulness of protocol-based resuscitation including the normalization of ScvO2 has been recently challenged by the ProCESS trial \[[@CR30]\], a randomized trial conducted in emergency departments in the very early phase of resuscitation of septic patients. This study showed no advantage in terms of survival with the protocol-based therapy including the normalization of S~cv~O~2~ as compared to usual care \[[@CR30]\]. Of note, the ProCESS trial population was quite different from that we studied in our work, in which we estimated the prevalence of S~cv~O~2~ and of persisting S~cv~O~2~ in ICU patients, after the initial phase of resuscitation. On the other hand, in 1995 Gattinoni *et al*. \[[@CR31]\] also showed that therapy aimed at normalizing the SvO2 value did not lead to better outcome than standard care in a general population of critically ill patients. Their results cannot be transposed to our study population as they included fewer than 25% of septic patients, and included them more than 48 hours after ICU admission \[[@CR31]\], a time frame quite different from that used for inclusion in our work. For these reasons we believe it is premature to abandon the concept of normalization of S~cv~O~2~ in severely septic patients admitted to the ICU for whom low S~cv~O~2~ cannot be neglected, given its association with increased day-28 mortality. Further studies are required to precisely identify which ICU patients would benefit from therapeutic strategies aimed at S~cv~O~2~ normalization.

The LOWESS plot (see Additional file [4](#MOESM4){ref-type="media"}) used to identify cutoff values of initial S~cv~O~2~ illustrates that below ScvO2 of 75%, the lower the S~cv~O~2~ the lower was the survival. Hence, S~cv~O~2~ \< 75% was also associated with day-28 mortality in our multivariate analysis. This cutoff of 75% for worse outcome in our septic patients is higher than that found in cardiac failure patients \[[@CR32],[@CR33]\]. This is consistent with the physiopathology of septic shock in which microcirculatory shunts lead to intra-organ oxygen extraction impairment that necessitates maintaining a high level of oxygen delivery to ensure adequate organ oxygen uptake \[[@CR34]\]. Beyond the confirmation that S~cv~O~2~ of 70% is an important threshold for patient outcome, our study also suggests that, in septic patients, S~cv~O~2~ of 75% could be an even more relevant target that best ensures that overall tissue oxygenation is adequate in the context of septic oxygen extraction impairment. However, the thresholds of S~cv~O~2~ that could be proposed after the visual inspection of the LOWESS plot were statistically estimated cutoff values in the entire study population that may not apply at the individual level. Therefore, S~cv~O~2~ value of 67% for instance does not necessarily place a given patient in a dangerous condition, and conversely an S~cv~O~2~ of 73% should not be seen as necessarily reassuring. In fact each individual patient probably has his/her own threshold from which it could be dangerous to deviate, depending on how his/her tissues are trained to extract oxygen in situations of high oxygen demand \[[@CR35]\] or insufficient oxygen transport, and depending on the intensity of the microcirculatory shunts \[[@CR36]\] linked to the severity of the sepsis process. In relation with this later issue, high values of ScvO2 may reflect the intensity of the microcirculatory derangements caused by sepsis. Some studies have suggested that either ScvO2 higher than 80% within the first 3 days in the ICU \[[@CR37]\] or ScvO2 higher than 90% in the emergency department \[[@CR38]\], were markers of poor prognosis. Indeed, although our study was underpowered to specifically examine the role of high values of S~cv~O~2~, we also observed that, beyond the threshold of 75%, the higher the S~cv~O~2~, the lower was the survival (see Additional file [4](#MOESM4){ref-type="media"}).

Limitations of the study {#Sec15}
------------------------

First, this study was not designed to seek for the reasons of low S~cv~O~2~. Since we have not systematically measured cardiac output, we cannot distinguish between the roles played by too-low oxygen delivery on the one hand and too-high oxygen demand on the other hand. Second, our study was clearly underpowered to draw conclusions about the significance of high S~cv~O~2~ values. Third, in view of our inclusion rate, selection bias cannot be definitely ruled out. However, patients were not selected on the basis of the variable of interest (S~cv~O~2~), which was not known during the screening/enrolment process. Additionally, enrolled and non enrolled patients' characteristics were similar (see Additional file [2](#MOESM2){ref-type="media"}). Moreover, as shown in Additional file [2](#MOESM2){ref-type="media"}, the proportion of patients with low S~cv~O~2~ consistently ranged from around 24% to 36% in subgroups of patients classified according to their cardiac or respiratory status, or to the timing and intensity of therapeutic interventions performed before inclusion. Fourth, S~cv~O~2~ was not measured by the same method in all participating centres, as four used standard blood gas analysers and six used co-oximeters. This might have distorted the accurate determination of cutoff values of ScvO2, because the limits of agreement between both methods are wide \[[@CR39]\]. However, this does not impair the general interpretation of our results as a majority (265/363) of the included patients had S~cv~O~2~ measured by co-oximetry and the link between low S~cv~O~2~ and day-28 mortality remained statistically significant in this patient subgroup.

Conclusion {#Sec16}
==========

Our study demonstrated that, in septic patients, low levels of S~cv~O~2~ in the first hours of ICU admission were frequent (\<70% for more than one quarter), even when clinical resuscitation endpoints are achieved and even when arterial lactate was normal. Importantly, S~cv~O~2~ in the first hours of ICU admission and/or six hours later was linked to day-28 mortality.

Key messages {#Sec17}
============

In septic shock patients, low S~cv~O~2~ (\<70%) is common in the first hours of admission to the ICUIn septic shock patients, low S~cv~O~2~ (\<70%) in the first hours of admission to the ICU is associated with increased day-28 mortalityIn addition to usual care, ICU protocol-based therapy targeting S~cv~O~2~ may be tested in controlled trials in septic patients with low or persisting low S~cv~O~2~ in the first hours of ICU admission

Additional files {#Sec18}
================
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